利用 Pfs47 和 Pfcpmp 基因序列对耐药性旅行相关恶性疟原虫进行地理分类(美国,2018-2021 年)。

IF 4.1 2区 医学 Q2 MICROBIOLOGY
Antimicrobial Agents and Chemotherapy Pub Date : 2024-12-05 Epub Date: 2024-11-12 DOI:10.1128/aac.01203-24
Edwin Pierre-Louis, Julia Kelley, Dhruviben Patel, Christina Carlson, Eldin Talundzic, David Jacobson, Joel Leonard Nicholas Barratt
{"title":"利用 Pfs47 和 Pfcpmp 基因序列对耐药性旅行相关恶性疟原虫进行地理分类(美国,2018-2021 年)。","authors":"Edwin Pierre-Louis, Julia Kelley, Dhruviben Patel, Christina Carlson, Eldin Talundzic, David Jacobson, Joel Leonard Nicholas Barratt","doi":"10.1128/aac.01203-24","DOIUrl":null,"url":null,"abstract":"<p><p>Travel-related malaria is regularly encountered in the United States, and the U.S. Centers for Disease Control and Prevention (CDC) characterizes <i>Plasmodium falciparum</i> drug-resistance genotypes routinely for travel-related cases. An important aspect of antimalarial drug resistance is understanding its geographic distribution. However, specimens submitted to CDC laboratories may have missing, incomplete, or inaccurate travel data. To complement genotyping for drug-resistance markers <i>Pfcrt</i>, <i>Pfmdr1</i>, <i>Pfk13</i>, <i>Pfdhps</i>, <i>Pfdhfr</i>, and <i>PfcytB</i> at CDC, amplicons of <i>Pfs47</i> and <i>Pfcpmp</i> are also sequenced as markers of geographic origin. Here, a bi-allele likelihood (BALK) classifier was trained using <i>Pfs47</i> and <i>Pfcpmp</i> sequences from published <i>P. falciparum</i> genomes of known geographic origin to classify clinical genotypes to a continent. Among <i>P. falciparum</i>-positive blood samples received at CDC for drug-resistance genotyping from 2018 to 2021 (<i>n</i> = 380), 240 included a travel history with the submission materials, though 6 were excluded due to low sequence quality. Classifications obtained for the remaining 234 were compared to their travel histories. Classification results were over 96% congruent with reported travel for clinical samples, and with collection sites for field isolates. Among travel-related samples, only two incongruent results occurred; a specimen submitted citing Costa Rican travel classified to Africa, and a specimen with travel referencing Sierra Leone classified to Asia. Subsequently, the classifier was applied to specimens with unreported travel histories (<i>n</i> = 140; 5 were excluded due to low sequence quality). For the remaining 135 samples, geographic classification data were paired with results generated using CDC's Malaria Resistance Surveillance (MaRS) protocol, which detects single-nucleotide polymorphisms in and generates haplotypes for <i>Pfcrt</i>, <i>Pfmdr1</i>, <i>Pfk13</i>, <i>Pfdhps</i>, <i>Pfdhfr</i>, and <i>PfcytB</i>. Given the importance of understanding the geographic distribution of antimalarial drug resistance, this work will complement domestic surveillance efforts by expanding knowledge on the geographic origin of drug-resistant <i>P. falciparum</i> entering the USA.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0120324"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619247/pdf/","citationCount":"0","resultStr":"{\"title\":\"Geo-classification of drug-resistant travel-associated <i>Plasmodium falciparum</i> using <i>Pfs47</i> and <i>Pfcpmp</i> gene sequences (USA, 2018-2021).\",\"authors\":\"Edwin Pierre-Louis, Julia Kelley, Dhruviben Patel, Christina Carlson, Eldin Talundzic, David Jacobson, Joel Leonard Nicholas Barratt\",\"doi\":\"10.1128/aac.01203-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Travel-related malaria is regularly encountered in the United States, and the U.S. Centers for Disease Control and Prevention (CDC) characterizes <i>Plasmodium falciparum</i> drug-resistance genotypes routinely for travel-related cases. An important aspect of antimalarial drug resistance is understanding its geographic distribution. However, specimens submitted to CDC laboratories may have missing, incomplete, or inaccurate travel data. To complement genotyping for drug-resistance markers <i>Pfcrt</i>, <i>Pfmdr1</i>, <i>Pfk13</i>, <i>Pfdhps</i>, <i>Pfdhfr</i>, and <i>PfcytB</i> at CDC, amplicons of <i>Pfs47</i> and <i>Pfcpmp</i> are also sequenced as markers of geographic origin. Here, a bi-allele likelihood (BALK) classifier was trained using <i>Pfs47</i> and <i>Pfcpmp</i> sequences from published <i>P. falciparum</i> genomes of known geographic origin to classify clinical genotypes to a continent. Among <i>P. falciparum</i>-positive blood samples received at CDC for drug-resistance genotyping from 2018 to 2021 (<i>n</i> = 380), 240 included a travel history with the submission materials, though 6 were excluded due to low sequence quality. Classifications obtained for the remaining 234 were compared to their travel histories. Classification results were over 96% congruent with reported travel for clinical samples, and with collection sites for field isolates. Among travel-related samples, only two incongruent results occurred; a specimen submitted citing Costa Rican travel classified to Africa, and a specimen with travel referencing Sierra Leone classified to Asia. Subsequently, the classifier was applied to specimens with unreported travel histories (<i>n</i> = 140; 5 were excluded due to low sequence quality). For the remaining 135 samples, geographic classification data were paired with results generated using CDC's Malaria Resistance Surveillance (MaRS) protocol, which detects single-nucleotide polymorphisms in and generates haplotypes for <i>Pfcrt</i>, <i>Pfmdr1</i>, <i>Pfk13</i>, <i>Pfdhps</i>, <i>Pfdhfr</i>, and <i>PfcytB</i>. Given the importance of understanding the geographic distribution of antimalarial drug resistance, this work will complement domestic surveillance efforts by expanding knowledge on the geographic origin of drug-resistant <i>P. falciparum</i> entering the USA.</p>\",\"PeriodicalId\":8152,\"journal\":{\"name\":\"Antimicrobial Agents and Chemotherapy\",\"volume\":\" \",\"pages\":\"e0120324\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619247/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antimicrobial Agents and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1128/aac.01203-24\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01203-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在美国,经常会遇到与旅行有关的疟疾,美国疾病控制和预防中心(CDC)对旅行相关病例的恶性疟原虫耐药性基因型进行了常规鉴定。抗疟药物耐药性的一个重要方面是了解其地理分布。然而,提交给疾病预防控制中心实验室的标本可能缺少、不完整或不准确的旅行数据。为了补充疾病预防控制中心对耐药性标记物 Pfcrt、Pfmdr1、Pfk13、Pfdhps、Pfdhfr 和 PfcytB 的基因分型,还对 Pfs47 和 Pfcpmp 的扩增子进行测序,作为地理来源的标记物。在此,我们使用已发表的已知地理来源恶性疟原虫基因组中的 Pfs47 和 Pfcpmp 序列训练了一个双等位基因似然法(BALK)分类器,以将临床基因型划分为一个洲。在中国疾病预防控制中心从 2018 年至 2021 年收到的进行耐药性基因分型的恶性疟原虫阳性血液样本(n = 380)中,有 240 份样本的送检材料中包含旅行史,但有 6 份样本因序列质量低而被排除在外。其余 234 份样本的分类结果与其旅行史进行了比较。分类结果与临床样本的旅行报告和野外分离样本的采集地点的一致性超过 96%。在与旅行有关的样本中,只有两个不一致的结果:一个样本提交时提到哥斯达黎加旅行,被归类为非洲样本;一个样本提到塞拉利昂旅行,被归类为亚洲样本。随后,分类器被应用于未报告旅行历史的标本(n = 140;5 个标本因序列质量低而被排除)。对于剩余的 135 份样本,地理分类数据与使用疾病预防控制中心疟疾抗药性监测(MaRS)方案生成的结果配对,该方案可检测 Pfcrt、Pfmdr1、Pfk13、Pfdhps、Pfdhfr 和 PfcytB 的单核苷酸多态性并生成单倍型。鉴于了解抗疟药物耐药性地理分布的重要性,这项工作将通过扩大对进入美国的耐药性恶性疟原虫地理来源的了解来补充国内的监测工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Geo-classification of drug-resistant travel-associated Plasmodium falciparum using Pfs47 and Pfcpmp gene sequences (USA, 2018-2021).

Travel-related malaria is regularly encountered in the United States, and the U.S. Centers for Disease Control and Prevention (CDC) characterizes Plasmodium falciparum drug-resistance genotypes routinely for travel-related cases. An important aspect of antimalarial drug resistance is understanding its geographic distribution. However, specimens submitted to CDC laboratories may have missing, incomplete, or inaccurate travel data. To complement genotyping for drug-resistance markers Pfcrt, Pfmdr1, Pfk13, Pfdhps, Pfdhfr, and PfcytB at CDC, amplicons of Pfs47 and Pfcpmp are also sequenced as markers of geographic origin. Here, a bi-allele likelihood (BALK) classifier was trained using Pfs47 and Pfcpmp sequences from published P. falciparum genomes of known geographic origin to classify clinical genotypes to a continent. Among P. falciparum-positive blood samples received at CDC for drug-resistance genotyping from 2018 to 2021 (n = 380), 240 included a travel history with the submission materials, though 6 were excluded due to low sequence quality. Classifications obtained for the remaining 234 were compared to their travel histories. Classification results were over 96% congruent with reported travel for clinical samples, and with collection sites for field isolates. Among travel-related samples, only two incongruent results occurred; a specimen submitted citing Costa Rican travel classified to Africa, and a specimen with travel referencing Sierra Leone classified to Asia. Subsequently, the classifier was applied to specimens with unreported travel histories (n = 140; 5 were excluded due to low sequence quality). For the remaining 135 samples, geographic classification data were paired with results generated using CDC's Malaria Resistance Surveillance (MaRS) protocol, which detects single-nucleotide polymorphisms in and generates haplotypes for Pfcrt, Pfmdr1, Pfk13, Pfdhps, Pfdhfr, and PfcytB. Given the importance of understanding the geographic distribution of antimalarial drug resistance, this work will complement domestic surveillance efforts by expanding knowledge on the geographic origin of drug-resistant P. falciparum entering the USA.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.00
自引率
8.20%
发文量
762
审稿时长
3 months
期刊介绍: Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信